Premium
Neuroprotective Effects of rhGLP‐1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury
Author(s) -
Jiang Daoli,
Wang Yitong,
Zang Yannan,
Liu Xiaofang,
Zhao Libo,
Wang Qian,
Liu Chang,
Feng Wanyu,
Yin Xiaoxing,
Fang Yi
Publication year - 2016
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21297
Subject(s) - neuroprotection , medicine , ischemia , stroke (engine) , enolase , anesthesia , pharmacology , streptozotocin , reperfusion injury , diabetes mellitus , myelin basic protein , endocrinology , myelin , central nervous system , immunohistochemistry , mechanical engineering , engineering
Preclinical ResearchThe aim of the present study was to evaluate the neuroprotective benefits of rhGLP‐1 in diabetic rats subjected to acute cerebral ischemia/reperfusion injury induced by middle cerebral artery occlusion/reperfusion (MCAO/R). Streptozotocin (STZ)‐induced diabetic rats were pretreated with rhGLP‐1 (10, 20, or 40 μg/kg ip, tid) for 14 days. During this time, body weight and fasting blood glucose levels were assessed. Rats were then subjected to MCAO 90 min/R 24 h. At 2 and 24 h of reperfusion, rats were evaluated for neurological deficits and blood samples were collected to analyze markers of brain injury. Rats were then sacrificed to assess the infarction volume. rhGLP‐1 pretreatment lowered blood glucose levels, improved neurological scores, attenuated infarct volumes, and reduced the blood levels of S100 calcium‐binding protein B (S100B), neuron‐specific enolase (NSE), and myelin basic protein (MBP). rhGLP‐1 has neuroprotective benefits in diabetic rats with cerebral ischemia/reperfusion injury and could potentially be used as a prophylatic neuroprotectant in diabetic patients at high risk of ischemic stroke. Drug Dev Res 77 : 124–133, 2016. © 2016 Wiley Periodicals, Inc.